Nerandomilast significantly slowed lung function decline in patients with IPF, with the 18 mg dose showing a 68.8 mL FVC decline reduction compared with placebo. The trial included 1177 patients ...

JNK India, operating in the Engineering - Heavy sector and classified as a Smallcap on the BSE, currently has its share price at ₹362.1. The stock has experienced fluctuations today, with a low ...

Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label ...

Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential ...

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC ...

Boehringer Ingelheim (BI) has unveiled results from two late-stage studies of nerandomilast in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The phase 3 FIBRONEER-IPF ...

Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC, shares trial findings from the FIBRONEER-IPF (NCT05321069) and FIBRONEER-ILD (NCT05321082) studies on ...

The presentation provided further insights into the successful Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100), highlighting the strength and durability of deupirfenidone’s treatment ...

Its pipeline is currently headed by VP01 (also known as C21), billed as a first-in-class oral angiotensin II type 2 receptor (AT2R) agonist, which is in phase 2 development for IPF and phase 3 for ...

Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label ...

One day after Boehringer Ingelheim presented so-so data from a successful trial of its highly touted idiopathic pulmonary fibrosis (IPF) candidate nerandomilast, PureTech has answered with results ...